CoChat

Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non–Small Cell Lung Cancer

Li, Anna, Yang, Jin-ji, Zhang, Xu-chao, Zhang, Zhou, Su, Jian, Gou, Lan-ying, Bai, Yu, Zhou, Qing, Yang, Zhenfan, Han-Zhang, Han, Zhong, Wen-Zhao, Chuai, Shannon, Zhang, Qi, Xie, Zhi, Gao, Hongfei, Chen, Huajun, Wang, Zhen, Wang, Zheng, Yang, Xue-ning, Wang, Bin-chao, Gan, Bin, Chen, Zhi-hong, Jiang, Ben-yuan, Wu, Si-pei, Liu, Si-yang, Xu, Chong-rui, Wu, Yi-long · 2017 · Clinical Cancer Research
Cited by 90

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Purpose: MET amplification, responsible for 20% of acquired resistance to EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non–small cell lung cancer (NSCLC), presents an attractive target. Numerous studies have conferred susceptibility of MET mutations and focal amplification to targeted MET-TKIs. However, the mechanism underlying MET-TKIs–induced resistance remains elusive. Experimental Design: We conducted a cohort of 12 patients with advanced NSCLC who developed resistance to a combinatorial therapy consisting of gefitinib and a type I MET-TKI. We performed capture-based targeted ultra-deep sequencing on serial tumor biopsies and plasmas ctDNA samples to detect and quantify genetic alterations. Results: We identified 2 newly acquired MET mutations, Y1248H and D1246N, in 2 patients and further confirmed their resistance against type I MET-TKIs in silco, in vitro, and in vivo. Interestingly, NIH3T3 cells harboring either mutation exhibited responses to type II MET-TKIs, suggesting sequential use of MET-TKIs may offer a more durable response. In addition, we also discovered that EGFR amplification may act as an alternative MET-TKI resistance mechanism. Conclusions: Our study provides insight into the diversity of mechanisms underlying MET-TKI–induced resistance and highlights the potential of sequential use of MET-TKIs. Clin Cancer Res; 23(16); 4929–37. ©2017 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-16-3273

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 90

Metadata

Authors
Li, A., Yang, J.-J., Zhang, X.-C., Zhang, Z., Su, J., Gou, L.-Y., Bai, Y., Zhou, Q., Yang, Z., Han-Zhang, H., Zhong, W.-Z., Chuai, S., Zhang, Q., Xie, Z., Gao, H., Chen, H., Wang, Z., Wang, Z., Yang, X.-N., Wang, B.-C., Gan, B., Chen, Z.-H., Jiang, B.-Y., Wu, S.-P., Liu, S.-Y., Xu, C.-R., & Wu, Y.-L.
Venue
Clinical Cancer Research
Published
2017-08-14
Volume
23
Issue
16
Pages
4929-4937
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2605418410
Cited by
90
References
4
FWCI
8.30
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non–Small Cell Lung Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-16-3273
The paper
Li, A., Yang, J.-J., Zhang, X.-C., Zhang, Z., Su, J., Gou, L.-Y., Bai, Y., Zhou, Q., Yang, Z., Han-Zhang, H., Zhong, W.-Z., Chuai, S., Zhang, Q., Xie, Z., Gao, H., Chen, H., Wang, Z., Wang, Z., Yang, X.-N., . . . Wu, Y.-L. (2017). Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non–Small Cell Lung Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-16-3273

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.